Nasdaq panel grants conditional continued listing for Longevity Health pending merger with 20/20 Biolabs by Sept 2, 2025

Longevity Health Holdings, Inc.

Nasdaq Hearings Panel granted continued listing condition: complete merger with 20/20 Biolabs and meet initial listing rules by Sept 2, 2025.
Company filed S-4 for merger on May 8, 2025, and effected 1-for-30 reverse stock split on May 12, 2025.
Panel based decision on review of financial statements and pro forma projections of combined company.
Chairman/CEO Rajiv Shukla stated focus on completing merger to satisfy Nasdaq requirements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.